Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The purpose of this study is to estimate and compare the objective response rate of SPI-1620 administered in combination with docetaxel in patients with NSCLC and to determine the safety of SPI-1620 when administered in combination with docetaxel.
Epistemonikos ID: bedf2a67e93324d814c997ebce5879d9374ec995
First added on: May 11, 2024